Switzerland’s Actelion has posted a reasonable set of figures for the first nine months of 2009 as sales of its lead drug Tracleer continue to drive growth.

Net profit on an adjusted basis was up 44% to 326.9 million Swiss francs, while revenues climbed 22% to 1.30 billion francs, the majority of which came from Tracleer (bosentan), for pulmonary arterial hypertension.

Tracleer sales were up 19% on the like, year-earlier period to 1.11 billion francs, though this was below analyst estimates. Of the firm’s other products, Ventavis (iloprost), an inhaled therapy for the treatment of PAH, leapt 57.5% to 101.6 million francs, while sales of Zavesca (miglustat), for patients with Gaucher disease for whom enzyme replacement therapy is not a therapeutic option, climbed 33% to 38.3 million francs.

Chief financial officer Andrew Oakley said that the business is continuing to perform strongly, despite an adverse currency effect that especially impacted third-quarter figures. He confirmed that full-year sales and cash earnings before interest and tax should rise 16%-19% and should be towards the upper end of those ranges, while top-line growth next year will be in the low-double digit range in local currencies.

Actelion is keen to reduce its reliance on Tracleer and has four compounds in Phase III, with a fifth expected to be initiated before the end of 2009. Leading the pipeline is almorexant for primary insomnia, which is partnered with GlaxoSmithKline, and late-stage data from a 700-patient study is expected to be unveiled soon.